Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 9.09%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.14, delivering a surprise of -16.67%. Over the last four quarters, the company has surpas ...

财务业绩 - 公司第二季度总收入达4810万美元,其中产品收入创纪录达4650万美元,同比增长26%[1][3] - 公司全年收入指引上调至1.9亿-2亿美元,年末现金余额指引为6000万-7500万美元[3] - 公司上半年总收入增长24.6%至8870.3万美元,其中Recorlev产品收入增长105.6%[8][9] - 公司现金、现金等价物和短期投资余额为7760万美元,较上年末增加[9] 产品表现 - Gvoke产品第二季度收入增长28.2%至2004.6万美元,处方量首次超过65,000份,市场份额达到34%[5] - Recorlev产品第二季度收入增长86.1%至1333.8万美元,患者人数增长124%[6] 管理层变动 - 公司任命John Shannon为新任CEO,Kevin McCulloch晋升为总裁兼首席运营官[2] 投资者关系 - 公司计划参加多个投资者会议,与投资者进行交流[10] 研发进展 - 公司管理层预计将于今年底前与FDA就XP-8121进行end-of-Phase 2会议[7] 财务状况 - 公司现金及现金等价物为5760.4万美元，较上年末增加[19] - 公司短期投资为1996.4万美元，较上年末增加[19] - 公司应收账款净额为4244.0万美元，较上年末增加[19] - 公司存货为4297.7万美元，较上年末增加[19] - 公司长期债务净额为23048.1万美元，较上年末增加[19] - 公司总股东权益为-1928.6万美元，较上年末减少[19]

From a technical perspective, Xeris Biopharma Holdings, Inc. (XERS) is looking like an interesting pick, as it just reached a key level of support. XERS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world. There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a posit ...

Use of technology We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. Proactive has always been a forward looking and enthusiastic technology adopter. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best ...

Table of Contents UNITED STATES Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION (Exact name of the registrant as specified in its charte ...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steven Pieper - CFO Conference Call Participants Oren Livnat - H.C. Wainwright & Co. Roanna Ruiz - Leerink Partners Rohan Mathur - Oppenheimer Kelly Close - Analyst Operator Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast. My name is Seth, and ...

Exhibit 99.1 XERIS BIOPHARMA REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND RECENT EVENTS Q1 2024 Total Revenue of $40.6M – up 22% over Q1 2023 Tightening full-year 2024 total revenue guidance to $175M-$200M Ended Q1 with $87.4M in cash, cash equivalents, and short-term investments, lowered borrowing rate of Hayfin debt by 2.05% Entered into a worldwide license agreement for XeriJect® formulation of teprotumumab Announced an exclusive worldwide agreement with Beta Bionics for development of a new XeriSol™ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1375 West Fulton Street, Suite 1300 (Address of principal executive offices) (Zip Code) (844) ...

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) Q4 2023 Earnings Conference Call March 6, 2024 8:30 AM ET Company Participants Paul Edick - Chairman, Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President, Investor Relations Conference Call Participants Oren Livnat - HC Wainwright Glen Santangelo - Jefferies Chase Knickerbocker - Craig Hallum Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler Operator Hello everyone and welcome to the Xeris fourth quarter a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-40880 XERIS BIOPHARMA HOLDINGS, INC. (Exact name of the registrant as specified in its ch ...